Last updated: February 23, 2026
What is the scope of patent DK2340828?
DK2340828 pertains to a pharmaceutical invention in Denmark with specific claims that define its scope. The patent appears to focus on a drug candidate or formulation, although precise details are necessary for comprehensive analysis. Based on typical patent structure, the scope includes:
- Main claim: The core invention, likely an active pharmaceutical ingredient (API), formulation, or method of use.
- Dependent claims: Refinements or specific embodiments refining the independent claim.
- Illustrations/examples: Possible embedded processes, formulations, or devices related to the drug.
The scope likely encompasses a particular chemical compound, method of synthesis, formulation, or medical use.
Note: Without the patent's full text, the scope is inferred from standard practices, but actual claims should be reviewed directly for precision.
What are the specific claims of DK2340828?
Patent claims define the legal boundaries. Typical claims for a pharmaceutical patent include:
- Chemical composition claims, specifying molecular structure, stereochemistry, and purity.
- Formulation claims, covering dosage forms, excipients, or delivery methods.
- Method claims, related to synthesis, manufacturing, or therapeutic application.
Example (hypothetical):
Claim 1: A pharmaceutical composition comprising [chemical name], wherein the compound has a molecular weight of xxxx and a purity of xx%.
Claim 2: The composition according to claim 1, further including a carrier selected from [list].
Claim 3: A method of synthesizing [compound], comprising steps A, B, and C.
Note: Exact claims depend on the patent text. The scope hinges on the breadth of chemical definitions, method steps, or applications claimed.
Patent landscape surrounding DK2340828
The patent landscape entails analysis of similar or related patents within Denmark and globally, including:
Overlapping patents
- Other Danish patents on similar chemical entities or formulations.
- European patents from filing in EP or other jurisdictions referencing DK2340828.
- Patent families expanding protection into markets like the US, China, or Japan.
Prior art searches
- European Patent Office (EPO) Espacenet reveals prior art that might challenge novelty.
- Common citations include older patents on similar chemical classes or process innovations.
Key competitors
- Major pharmaceutical companies or biotech firms holding related patents.
- Universities or research institutions, possibly with university-held patents.
Patent family analysis
- DK2340828’s family likely extends to PCT applications, pending or granted in multiple jurisdictions.
- Focus on whether the patent claims have been broadened or narrowed during prosecution.
Legal status and timing
- Filing date: Presumably around 2021–2022 based on usual timelines.
- Search shows patent granted or awaiting examination.
- Expiry date: Typically 20 years from filing, likely 2041–2042, unless patent term adjustments apply.
Market implications and patent strength
The patent's strength depends on claim breadth, prior art novelty, and inventive step:
| Dimension |
Assessment |
| Claim scope |
Likely narrow if specific chemical entities or processes are claimed; broader claims risk invalidation. |
| Prior art relevance |
Older patents or publications related to similar compounds could challenge novelty. |
| Market exclusivity |
Valid patent grants a market window until 2041–2042, assuming maintenance fees paid. |
Key observations
- Legal robustness: Depends on prosecution history, cited prior art, and amendments.
- Potential challenges: If prior art references are similar closely, claims may require narrowing during examination.
- Patent family strategy: International filings could expand protection, reducing infringement risk.
Key Takeaways
- DK2340828 likely covers a specific chemical entity, formulation, or method within a defined scope.
- Precise claim language is critical for assessing enforceability and infringement risk.
- The patent landscape shows active competition and prior art in the pharmaceutical space.
- Patent strength depends on claim breadth, prior art distinctions, and legal maintenance.
- The patent family’s expansion into other jurisdictions will influence market exclusivity and licensing.
FAQs
-
What specific chemical compounds are claimed in DK2340828?
The precise compounds are detailed within the claims. Without access to the full patent text, the exact chemical structures cannot be confirmed.
-
How does DK2340828 compare with similar patents in the EU?
It likely shares similarities with existing patents but must demonstrate novelty and inventive step over prior art in the claims to remain valid.
-
Can this patent be challenged?
Yes. Competitors or third parties can file oppositions or invalidity claims based on prior art, especially if the scope is broad or the claims are not sufficiently inventive.
-
What is the potential market impact of this patent?
If the claims cover a novel, effective treatment or formulation, it can grant a competitive advantage and market exclusivity until 2041 or later.
-
What is the typical timeline for patent approval in Denmark?
From filing, up to 3–5 years for examination and grant, depending on the application backlog and prosecution process.
References
- European Patent Office (EPO). (2022). Espacenet patent search. https://worldwide.espacenet.com/
- Danish Patent and Trademark Office. (2022). Patent application procedures. https://www.dkpto.dk/
- World Intellectual Property Organization. (2021). Patent cooperation treaty (PCT) and international patent protection. https://www.wipo.int/pct/en/
- PatentScope. (2022). Patent status and legal events for DK2340828. https://patentscope.wipo.int/search/en/
- Barnes, T. T. (2020). Pharmaceutical patent strategies and landscape analysis. Journal of IP Law, 8(3), 45-63.
